MedTrace Logo

Carbonic Anhydrase IX Enzyme in Triple Negative Breast Carcinoma

NCT06309459 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-03-13

No results posted yet for this study

Summary

Triple-negative breast carcinoma is characterized by the absence of estrogen receptors, progesterone receptors, and HER2/neu receptors. Carbonic anhydrase IX (CA IX) is a tumor-associated cell surface glycoprotein that is involved in adaptation to hypoxia-induced acidosis and plays a role in cancer progression. This study aimed to investigate CA IX expression in TNBC and its relationship with treatment effect.

Conditions

Interventions

DIAGNOSTIC_TEST

Carbonic anhydrase staining levels

CA IX is a transmembrane protein, it exhibits cytoplasmic membrane staining. Immunohistochemically positive cells were graded as Low staining if they constituted \<10% of the total and high staining if they constituted ≥ 10% (15).

Sponsors & Collaborators

  • Kahramanmaras Sutcu Imam University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-01
Primary Completion
2023-05-01
Completion
2023-05-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06309459 on ClinicalTrials.gov